|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Otsuka Pharmaceutical Co., Ltd.-Deals & Alliances Report
|
Mar 2011 |
£380 |
100% |
Otsuka Pharmaceutical Co - Product Pipeline Review
Q4 2010
|
Nov 2010 |
£315 |
96% |
Chugai Pharmaceutical Co. Ltd - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
83% |
MethylGene Inc – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
82% |
|
Partnering Agreements with Otsuka 2010
|
Jan 2010 |
£630 |
82% |
Dry Eye Syndrome Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Mar 2011 |
£1,265 |
81% |
Hyponatremia - Pipeline Review
H2 2011
|
Aug 2011 |
£315 |
79% |
Bristol-Myers Squibb Company - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
78% |
Eiken Chemical Co.,Ltd. - Medical Equipment
Deals and Alliances Profile
|
Jul 2009 |
£160 |
78% |
|
Inflammatory Bowel Disease Therapeutics
|
Apr 2010 |
£2,500 |
77% |
Galenea Corp. - Product Pipeline Review
Q4 2010
|
Dec 2010 |
£315 |
77% |
Dong-A Pharmaceutical Co., Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
76% |
Partnering and M&A Yearbook
2012
|
Jan 2012 |
£2,210 |
76% |
Partnering Yearbook
2012
|
Jan 2012 |
£1,895 |
75% |
ISTA Pharmaceuticals, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
75% |
Open-Angle Glaucoma - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
74% |
Kyowa Hakko Kirin Co., Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
74% |
Partnering Agreements with Bigpharma
3rd Edition
|
Oct 2010 |
£630 |
72% |
|
Opthalmic Pharmaceutical Drugs
|
Oct 2010 |
£2,845 |
70% |
Prospects for Pharma Mergers, Acquisitions and Alliances
2010-2020
|
Jul 2010 |
£1,499 |
65% |
Glaucoma - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
63% |
|
Imaging Agents
|
Feb 2011 |
£2,845 |
63% |
|
CNS Therapeutics
|
May 2008 |
£2,500 |
63% |
Ocular Hypertension - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
62% |
Drug Delivery Partnering Terms and Agreements in Pharma and Biotech
2nd Edition
|
Nov 2010 |
£1,705 |
62% |
Pancreatic Cancer - Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
62% |
Option & Evaluation Agreements in Pharma and Biotech
2nd edition
|
Jun 2010 |
£1,705 |
61% |
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
61% |
|
Asia Pacific Anesthesia and Respiratory Devices Investment Opportunities, Analysis and Forecasts to 2015
|
Jun 2009 |
£1,580 |
60% |
Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020
Volume I 2011
|
Apr 2011 |
£3,160 |
59% |
